OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Interpreting the results of the VERTIS‐CV trial: Is this the end of the “class effect” perspective?
Theocharis Koufakis, Νικόλαος Παπάνας, George Dimitriadis, et al.
Journal of Diabetes (2020) Vol. 12, Iss. 12, pp. 942-945
Open Access | Times Cited: 11

Showing 11 citing articles:

Management of post‐transplant diabetes: immunosuppression, early prevention, and novel antidiabetics
Manfred Hecking, Adnan Sharif, Kathrin Eller, et al.
Transplant International (2020) Vol. 34, Iss. 1, pp. 27-48
Open Access | Times Cited: 95

Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?
Theocharis Koufakis, Омар Мустафа, Vasilis Tsimihodimos, et al.
Drugs (2021) Vol. 81, Iss. 12, pp. 1365-1371
Open Access | Times Cited: 22

Comparing the clinical outcomes across different sodium/glucose cotransporter 2 (SGLT2) inhibitors in heart failure patients: a systematic review and network meta-analysis of randomized controlled trials
Yao Hao Teo, Celine Shuen Yin Yoong, Nicholas Syn, et al.
European Journal of Clinical Pharmacology (2021) Vol. 77, Iss. 10, pp. 1453-1464
Closed Access | Times Cited: 16

Glucagon-like peptide-1 receptor agonists and sodium−glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect
Ricardo Gómez‐Huelgas, Jaime Sanz‐Cánovas, Lidia Cobos-Palacios, et al.
European Journal of Internal Medicine (2021) Vol. 96, pp. 26-33
Closed Access | Times Cited: 11

Study on Differences of Metabolites among Different Ganoderma Species with Comprehensive Metabolomics
Solongo Khadbaatar, Bao Hai-ying, Xusheng Gao, et al.
Journal of Fungi (2024) Vol. 10, Iss. 8, pp. 524-524
Open Access | Times Cited: 1

A Horse, a Jockey, and a Therapeutic Dilemma: Choosing the Best Option for a Patient with Diabetes and Coronary Artery Disease
Theocharis Koufakis, Evangelos Liberopoulos, Kalliopi Kotsa
American Journal of Cardiovascular Drugs (2022) Vol. 22, Iss. 4, pp. 357-361
Closed Access | Times Cited: 7

Treatment options following metformin in primary prevention populations with type 2 diabetes: which is the right road to take?
Theocharis Koufakis, Νικόλαος Παπάνας, Pantelis Zebekakis, et al.
Expert Review of Clinical Pharmacology (2021) Vol. 14, Iss. 10, pp. 1189-1192
Open Access | Times Cited: 9

The effect of dapagliflozin on ventricular arrhythmias, cardiac arrest, or sudden death in people with heart failure: a tick in another box for sodium-glucose cotransporter 2 inhibitors
Theocharis Koufakis, George Giannakoulas, Pantelis Zebekakis, et al.
Expert Opinion on Pharmacotherapy (2021) Vol. 23, Iss. 3, pp. 321-325
Closed Access | Times Cited: 9

Dual sodium-glucose cotransporter (SGLT) 1/2 versus pure SGLT2 inhibitors: two distinct drug categories or one class with multiple faces?
Theocharis Koufakis, Michael Doumas, Pantelis Zebekakis, et al.
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 13, pp. 1497-1502
Closed Access | Times Cited: 6

Sodium-Glucose Co-transporter 2 Inhibitors Versus Metformin as the First-Line Treatment for Type 2 Diabetes: Is It Time for a Revolution?
Theocharis Koufakis, Athanasia Papazafiropoulou, Konstantinos Makrilakis, et al.
Cardiovascular Drugs and Therapy (2021) Vol. 37, Iss. 2, pp. 315-321
Closed Access | Times Cited: 4

Sodium–glucose co‐transporter‐2 inhibitors and arterial stiffness: Class effect or drug effect?
Dimitrios Patoulias, Christodoulos Papadopoulos, Alexandra Katsimardou, et al.
Journal of Clinical Hypertension (2020) Vol. 22, Iss. 12, pp. 2389-2390
Open Access | Times Cited: 2

Page 1

Scroll to top